Reviva Pharmaceuticals Holdings, Inc. - RVPH STOCK NEWS

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its CEO Laxminarayan Bhat will present at the 35th Annual Roth Conference from March 12-14, 2023, in Dana Point, California. The presentation will take place on March 13 at 3:00 p.m. PT. Reviva focuses on developing therapies for unmet medical needs, particularly in central nervous system, cardiovascular, metabolic, and inflammatory diseases. Their pipeline includes drug candidates brilaroxazine (RP5063) and RP1208. For more details, visit the webcast link.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a clinical-stage pharmaceutical company, will have its Founder and CEO, Laxminarayan Bhat, present at the BIO CEO and Investor Conference from February 6–9, 2023 in New York. The presentation is scheduled for February 6 at 11:30 p.m. EST. Reviva focuses on developing therapies for unmet medical needs in central nervous system, cardiovascular, metabolic, and inflammatory diseases. Their pipeline includes drug candidates RP5063 (brilaroxazine) and RP1208, both with composition of matter patents in multiple regions.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced progress in its Phase 3 RECOVER trial for brilaroxazine, targeting schizophrenia, with top-line data expected in mid-2023. Approximately 40% of patients have been treated with no serious adverse events reported. The company secured $8.5 million in funding to support this trial. Additionally, they completed a drug-drug interaction study showing brilaroxazine's favorable safety profile. Reviva aims to explore other indications, representing a combined market opportunity exceeding $70 billion. Upcoming milestones include potential NDA submission in 2025.

Reviva Pharmaceuticals Holdings announces positive results from a clinical drug-drug interaction study for brilaroxazine, a serotonin/dopamine modulator, essential for schizophrenia treatment. The study reinforces brilaroxazine's safety profile, showing no significant adverse interactions with CYP3A4 enzyme inhibitors. Topline data from the pivotal Phase 3 RECOVER trial is expected mid-2023, involving 400 patients over a 28-day regimen. The FDA may consider a 'Superior Safety' label for brilaroxazine based on positive Phase 3 results.

Reviva Pharmaceuticals (NASDAQ: RVPH) reported significant progress in its pivotal Phase 3 RECOVER trial for brilaroxazine, with over 30% patient enrollment across U.S. sites and expansion into Europe and India expected by year-end. Financially, the company recorded a net loss of $3.5 million for Q3 2022, compared to $2.3 million in Q3 2021, and had $23.2 million in cash as of September 30, 2022. Reviva anticipates topline data for the trial in mid-2023 and is exploring partnerships for further development in various neuropsychiatric and pulmonary indications.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced significant progress in its Phase 3 RECOVER study for brilaroxazine, a treatment for schizophrenia, with over 30% enrollment in the U.S. and ongoing sites in Europe. The company expects to begin enrollment in Asia by November 2022. No major safety concerns have been reported in the trial, which is designed to assess brilaroxazine's efficacy across approximately 400 patients. Topline data is anticipated in mid-2023, reinforcing the potential of brilaroxazine to address the needs of approximately 24 million individuals living with schizophrenia globally.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announced that an interview with its Founder and CEO, Dr. Laxminarayan Bhat, will air on The RedChip Money Report on Bloomberg TV, on October 15 at 7 p.m. ET. The interview will cover the company's insider support and expected outcomes from Phase 3 trials in mid-2023. Reviva focuses on developing therapies for unmet medical needs in CNS, respiratory, and metabolic diseases. The firm is advancing two drug candidates, RP5063 and RP1208, both of which have received patent protection.

Reviva Pharmaceuticals (NASDAQ: RVPH) announced participation in the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. CEO Laxminarayan Bhat will present a webcast at 9:00 AM ET, followed by a fireside chat and Q&A session. Investors can engage in virtual one-on-one meetings with management. Reviva focuses on developing therapies for unmet medical needs in CNS, cardiovascular, metabolic, and inflammatory diseases, with two drug candidates, RP5063 and RP1208, in its pipeline.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its Founder and CEO, Laxminarayan Bhat, will present at the H.C. Wainwright Global Investment Conference from September 12-14, 2022. Investors can participate in virtual and in-person meetings in New York, NY. Reviva focuses on developing therapies for unmet medical needs, particularly in the central nervous system, cardiovascular, metabolic, and inflammatory diseases. The company’s pipeline includes drug candidates RP5063 and RP1208, both of which have received patent protections.